142 related articles for article (PubMed ID: 19158312)
1. Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese.
Matsunaga M; Yamazaki H; Kiyotani K; Iwano S; Saruwatari J; Nakagawa K; Soyama A; Ozawa S; Sawada J; Kashiyama E; Kinoshita M; Kamataki T
Drug Metab Dispos; 2009 Apr; 37(4):699-701. PubMed ID: 19158312
[TBL] [Abstract][Full Text] [Related]
2. Metabolic activity of dextromethorphan O-demethylation in healthy Japanese volunteers carrying duplicated CYP2D6 genes: duplicated allele of CYP2D6*10 does not increase CYP2D6 metabolic activity.
Ishiguro A; Kubota T; Ishikawa H; Iga T
Clin Chim Acta; 2004 Jun; 344(1-2):201-4. PubMed ID: 15149890
[TBL] [Abstract][Full Text] [Related]
3. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
Yu A; Dong H; Lang D; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510
[TBL] [Abstract][Full Text] [Related]
4. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6.
Fukuda T; Nishida Y; Imaoka S; Hiroi T; Naohara M; Funae Y; Azuma J
Arch Biochem Biophys; 2000 Aug; 380(2):303-8. PubMed ID: 10933885
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T
Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754
[TBL] [Abstract][Full Text] [Related]
6. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
8. Tryptamine: a possible endogenous substrate for CYP2D6.
Martínez C; Agúndez JA; Gervasini G; Martín R; Benítez J
Pharmacogenetics; 1997 Apr; 7(2):85-93. PubMed ID: 9170145
[TBL] [Abstract][Full Text] [Related]
9. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A; Kneller BM; Rettie AE; Haining RL
J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6-Mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528.
Kotsuma M; Tokui T; Ishizuka-Ozeki T; Honda T; Iwabuchi H; Murai T; Ikeda T; Saji H
Drug Metab Dispos; 2008 Mar; 36(3):529-34. PubMed ID: 18056254
[TBL] [Abstract][Full Text] [Related]
11. New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes.
Li L; Pan RM; Porter TD; Jensen NS; Silber P; Russo G; Tine JA; Heim J; Ring B; Wedlund PJ
Drug Metab Dispos; 2006 Aug; 34(8):1411-6. PubMed ID: 16679388
[TBL] [Abstract][Full Text] [Related]
12. Developmental changes in human liver CYP2D6 expression.
Stevens JC; Marsh SA; Zaya MJ; Regina KJ; Divakaran K; Le M; Hines RN
Drug Metab Dispos; 2008 Aug; 36(8):1587-93. PubMed ID: 18474679
[TBL] [Abstract][Full Text] [Related]
13. Development of a rapid and sensitive high-performance liquid chromatographic method to determine CYP2D6 phenotype in human liver microsomes.
Rege B; March C; Sarkar MA
Biomed Chromatogr; 2002 Feb; 16(1):31-40. PubMed ID: 11816009
[TBL] [Abstract][Full Text] [Related]
14. Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol, and dextromethorphan.
Uno Y; Uehara S; Kohara S; Murayama N; Yamazaki H
Drug Metab Dispos; 2010 Sep; 38(9):1486-92. PubMed ID: 20501912
[TBL] [Abstract][Full Text] [Related]
15. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans.
Casner PR
J Clin Pharmacol; 2005 Nov; 45(11):1230-5. PubMed ID: 16239355
[TBL] [Abstract][Full Text] [Related]
16. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.
Niwa T; Hiroi T; Tsuzuki D; Yamamoto S; Narimatsu S; Fukuda T; Azuma J; Funae Y
Brain Res Mol Brain Res; 2004 Oct; 129(1-2):117-23. PubMed ID: 15469888
[TBL] [Abstract][Full Text] [Related]
17. Effect of sodium ozagrel on the activity of rat CYP2D6.
Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D
Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M
Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265
[TBL] [Abstract][Full Text] [Related]
19. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR
Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457
[TBL] [Abstract][Full Text] [Related]
20. A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6.
Toscano C; Raimundo S; Klein K; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):767-70. PubMed ID: 17001296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
